Compare Stocks → 4x Better than Bitcoin (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADILNASDAQ:ADXNNASDAQ:DFFNNASDAQ:MTP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILAdial Pharmaceuticals$1.40+2.2%$1.46$0.77▼$14.00$2.32M1.524.12 million shs185,186 shsADXNAddex Therapeutics$12.35+2.5%$10.48$5.00▼$23.40$12.23M1.629,840 shs4,210 shsDFFNDiffusion Pharmaceuticals$4.40+11.7%$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsMTPBiodexa Pharmaceuticals$1.95$0.29▼$5.25$6.18M2.2957,354 shs164,300 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILAdial Pharmaceuticals+2.56%-20.00%+68.05%-20.90%-84.70%ADXNAddex Therapeutics+0.08%+1.23%+19.90%+110.03%-45.35%DFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-39.64%MTPBiodexa Pharmaceuticals0.00%0.00%0.00%0.00%-75.00%the most reliable asset on earth is making a comeback (Ad)Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click HereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILAdial PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AADXNAddex Therapeutics0.2274 of 5 stars0.03.00.00.01.90.80.6DFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILAdial PharmaceuticalsN/AN/AN/AN/AADXNAddex Therapeutics2.00HoldN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILAdial PharmaceuticalsN/AN/AN/AN/A$3.17 per shareN/AADXNAddex Therapeutics$1.51M8.10N/AN/A$8.01 per share1.54DFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AMTPBiodexa Pharmaceuticals$800K0.00N/AN/A$5.67 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILAdial Pharmaceuticals-$12.73M-$5.72N/AN/AN/AN/A-332.86%-212.05%4/4/2024 (Estimated)ADXNAddex Therapeutics-$21.80M-$19.27N/AN/AN/A-550.78%-236.83%-147.15%4/4/2024 (Estimated)DFFNDiffusion Pharmaceuticals-$15.59MN/A0.00∞N/AN/A-69.96%-62.98%N/AMTPBiodexa Pharmaceuticals-$7.51MN/A0.00N/AN/AN/AN/AN/AN/ALatest ADXN, DFFN, MTP, and ADIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AADILAdial PharmaceuticalsN/A-$0.76-$0.76N/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILAdial PharmaceuticalsN/AN/AN/AN/AN/AADXNAddex TherapeuticsN/AN/AN/AN/AN/ADFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADILAdial PharmaceuticalsN/A2.152.15ADXNAddex TherapeuticsN/A2.972.97DFFNDiffusion PharmaceuticalsN/A10.7110.71MTPBiodexa PharmaceuticalsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILAdial Pharmaceuticals16.41%ADXNAddex Therapeutics16.14%DFFNDiffusion Pharmaceuticals9.95%MTPBiodexa Pharmaceuticals4.21%Insider OwnershipCompanyInsider OwnershipADILAdial Pharmaceuticals14.47%ADXNAddex Therapeutics15.00%DFFNDiffusion Pharmaceuticals1.80%MTPBiodexa Pharmaceuticals0.34%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADILAdial Pharmaceuticals161.66 million1.42 millionNo DataADXNAddex Therapeutics24990,000843,000Not OptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableMTPBiodexa Pharmaceuticals1821.67 million21.60 millionNot OptionableADXN, DFFN, MTP, and ADIL HeadlinesSourceHeadlineBiodex stock slides 7% amid data for two drug studiesmsn.com - February 23 at 8:57 PMWhy Is Brain Cancer Focused-Biodexa Pharmaceuticals Stock Trading Higher Today?msn.com - February 13 at 3:11 PMCrude Oil Rises Over 1%; Biodexa Pharmaceuticals Shares Plungemsn.com - December 19 at 4:01 PMBiodexa Announces Pricing of $5.2 Million Underwritten Public Offeringtmcnet.com - December 19 at 9:37 AMBiodexa Pharmaceuticals PLC Announces Results Of Appeal Of Delisting Determinationbenzinga.com - July 8 at 9:54 AMBDRX Biodexa Pharmaceuticals Plcseekingalpha.com - April 25 at 8:04 PMBiodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equityfinance.yahoo.com - April 4 at 3:25 PMWhy Is Midatech Pharma (BDRX) Stock Up 64% Today?investorplace.com - March 28 at 9:17 AMMidatech Pharma PLC Announces Private Placement Raising US $6.0 millionfinance.yahoo.com - February 9 at 3:29 PMBioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plcfinancialpost.com - January 23 at 9:28 AMMidatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Studyfinance.yahoo.com - January 12 at 7:34 AMBIOAF: Merger with Midatech Pharmafinance.yahoo.com - January 3 at 3:29 PMMidatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Incfinance.yahoo.com - December 13 at 1:49 PMBioasis Technologies Inc. Announces Merger with Midatech Pharma plcfinance.yahoo.com - December 13 at 1:49 PMMTP Midatech Pharma plcseekingalpha.com - October 11 at 12:50 PMMidatech Pharma Will Need Extra Financing in 1Q 2023; Mulling Optionsmarketwatch.com - September 14 at 10:02 PMMidatech Pharma PLC Announces ADR Ratio Changefinance.yahoo.com - September 14 at 10:17 AMMidatech Pharma PLC Newsthestreet.com - August 3 at 12:44 AMMidatech Pharma PLC Announces MTX110 Development for the Treatment of Gliomafinance.yahoo.com - June 21 at 4:04 AMMidatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022yahoo.com - June 10 at 3:47 AMMidatech Pharma: MTX110’s Path To Market Fast-Tracked In RGBMuk.investing.com - June 7 at 8:40 PMMidatech Pharma plc [MTP] Revenue clocked in at $0.70 million, down -28.57% YTD: What’s Next?dbtnews.com - June 2 at 6:44 AMMidatech Pharma climbs on FDA’s Fast Track Designation for brain tumor candidateseekingalpha.com - June 1 at 10:13 AMMidatech's investigational glioblastoma treatment gets Fast Track statusfinance.yahoo.com - June 1 at 10:13 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdial PharmaceuticalsNASDAQ:ADILAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Addex TherapeuticsNASDAQ:ADXNAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Diffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.Biodexa PharmaceuticalsNASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.